Innovation
Healthcare
FEATURED

Latest FDA-Approved Preventive Treatment For Migraine, Qulipta, Enters A Highly Competitive Market

On September 28th, the FDA approved a once-daily oral medicine, Qulipta (atogepant), for preventive treatment of episodic migraine in adults. It is the second FDA-approved, oral anti-CGRP drug for preventing migraine. The first was Nurtec ODT (rimegepant).

More from Healthcare
Oct 3, 2021

Making Health A Priority At Business Schools

Where will business schools have the most impact in the next ten to twenty years? With a global pandemic as well as health threats such as obesity, heart disease, air pollution adding to the challenge of an ageing society, it's no wonder health care is now a priority on the business school agenda.